OMEROS Business Summary

Omeros Corporation (OMER) is a commercial-stage biopharmaceutical company that generates revenue through a multi-tiered model comprising direct product sales, royalty streams, and strategic licensing milestones. Following the landmark FDA approval of YARTEMLEA (narsoplimab-wuug) in December 2025, the company transitioned to commercial operations with its first shipments in January 2026 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This revenue is supplemented by ongoing royalties from OMIDRIA, an ophthalmic solution sold to Rayner Surgical, and a high-value partnership with Novo Nordisk for the MASP-3 inhibitor zaltenibart, which provided a $240 million upfront payment in late 2025. Omeros operates primarily in the complement-mediated disease segment, with additional pipelines in addictive disorders and immuno-oncology. It competes directly with major players in the complement space, including AstraZeneca (Ultomiris), Apellis Pharmaceuticals, and Alexion, distinguishing itself as the market leader in lectin pathway inhibition and the provider of the only approved therapy for TA-TMA. Omeros was founded in 1994 by Dr. Gregory A. Demopulos, who continues to serve as Chairman, President, and CEO. Dr. Demopulos, a Stanford and Duke-trained orthopedic surgeon, is a prolific inventor with over 1,000 patents and a recipient of the Prix Galien Canada Research Award. The leadership team includes Chief Commercial Officer Nadia Dac, formerly of AbbVie and Alder BioPharmaceuticals, and Chief Scientific Officer Dr. George A. Gaitanaris, who oversees the company’s proprietary MASP platform. Financial operations are led by David J. Borges, VP of Finance and Chief Accounting Officer, while Dr. Andreas Grauer serves as Chief Medical Officer. The company’s board of directors features high-profile figures such as Dr. Leroy Hood, a pioneer in biotechnology and National Medal of Science recipient, and Dr. Rajiv Shah, President of the Rockefeller Foundation. Notable institutional backing includes Polar Asset Management Partners, which recently participated in a significant direct equity offering to support the commercial launch of YARTEMLEA.